The humanized anti–Clever-1 antibody bexmarilimab was generated and produced by Abzena. The anti–Clever-1 parental antibody 3–372 (InVivo Biotech), the humanized anti–Clever-1 antibody FP-1304 without the L248E mutation (Antitope Ltd), rituximab (Roche), alemtuzumab (Genzyme), cetuximab (Merck Healthcare KGaA), and the isotype control antibodies human IgG4 (Biolegend) and rat IgG2a (Biolegend) were used as references and controls as indicated in the respective method descriptions.
KG-1 human acute myelogenous leukemia and human Jurkat cells were purchased from ATCC and NS0 murine myeloma cells from the European Collection of Authenticated Cell Cultures (ECACC). The cell lines were routinely tested for Mycoplasma with PCR Mycoplasma Test Kit I/C (Promocell). Cell line authentication was not performed as the cells were used from a master cell bank (<5 passages) created from the original vial.
KG-1 human acute myelogenous leukemia and human Jurkat cells were purchased from ATCC and NS0 murine myeloma cells from the European Collection of Authenticated Cell Cultures (ECACC). The cell lines were routinely tested for Mycoplasma with PCR Mycoplasma Test Kit I/C (Promocell). Cell line authentication was not performed as the cells were used from a master cell bank (<5 passages) created from the original vial.